Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Protagonist Therapeutics, Inc. - Common Stock
(NQ:
PTGX
)
147.78
-0.40 (-0.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Protagonist Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
September 08, 2026
From
Protagonist Therapeutics
Via
ACCESS Newswire
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
September 02, 2026
From
Protagonist Therapeutics
Via
ACCESS Newswire
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
August 28, 2026
From
Protagonist Therapeutics
Via
ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Awards
August 18, 2026
From
Protagonist Therapeutics
Via
ACCESS Newswire
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 05, 2026
From
Protagonist Therapeutics
Via
ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Awards
August 04, 2026
From
Protagonist Therapeutics
Via
ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Awards
July 16, 2026
From
Protagonist Therapeutics
Via
ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Awards
July 01, 2026
From
Protagonist Therapeutics
Via
ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Awards
June 16, 2026
From
Protagonist Therapeutics
Via
ACCESS Newswire
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
June 01, 2026
Via
ACCESS Newswire
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
May 28, 2026
Via
ACCESS Newswire
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 05, 2026
Via
ACCESS Newswire
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
April 28, 2026
Via
ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Awards
April 16, 2026
Via
ACCESS Newswire
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 28, 2026
Via
ACCESS Newswire
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
March 18, 2026
Via
ACCESS Newswire
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
March 02, 2026
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026
Via
ACCESS Newswire
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026
Via
ACCESS Newswire
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026
February 24, 2026
Via
ACCESS Newswire
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
January 07, 2026
Via
ACCESS Newswire
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
January 05, 2026
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
November 27, 2025
Via
ACCESS Newswire
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 06, 2025
Via
ACCESS Newswire
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
November 03, 2025
Via
ACCESS Newswire
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
October 27, 2025
Via
ACCESS Newswire
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
October 20, 2025
Via
AB Newswire
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
October 07, 2025
Via
ACCESS Newswire
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
September 17, 2025
Via
ACCESS Newswire
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
September 15, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
